News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Barrier Therapeutics, Inc. (BTRX) To Retain Worldwide Rights To Hyphanox(TM)



10/19/2005 5:12:29 PM

PRINCETON, NJ--(MARKET WIRE)--Sep 22, 2005 -- Barrier Therapeutics, Inc. (NasdaqNM:BTRX - News), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that it will retain worldwide rights for all licensed indications to its oral antifungal product candidate, Hyphanox(TM). Janssen Pharmaceutica Products, L.P. held an option for the rights to Hyphanox on a geographic region by region basis, which had been negotiated as part of Barrier's initial license to the product rights. Barrier triggered the option based on the results of the recently completed Phase 3 non-inferiority clinical trial in vaginal candidiasis, in which Hyphanox demonstrated clinical efficacy that was not inferior to fluconazole, but did not reach the primary regulatory endpoint of therapeutic cure.

Read at Market Wired


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES